An overview of recent advances in the prevention of erythroblastosis fetalis

An overview of recent advances in the prevention of erythroblastosis fetalis Aishwarya Balasubramaniam Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamil Nadu, India V. Santhosh Kumar Department of Pharmacology, School of Pharmaceutical Sciences, Vels Institute of Science Technology and Advanced Studies, Chennai, Tamil Nadu, India S. Priya Department of Safety Operations, IQVIA Private Limited, Bengaluru, Karnataka, India

Erythroblastosis fetalis is one of the leading causes of death among newborns and fetuses in India. This condition is characterized by maternal immunoglobin G antibodies destroying the red blood cells (RBCs) of the neonate or fetus, resulting in potentially life-threatening consequences. When a mother with an Rh-positive blood group has a fetus with an Rh-negative blood group, the fetal RBCs trigger maternal antibodies against Rh-antigens. Anti-D antibodies are activated as a result of this process, which is known as isoimmunization. As a result of the antibody reaction, all of the erythrocytes are destroyed, resulting in hemolysis, bilirubin release, and anemia. Intravascular transfusions and intraperitoneal transfusions are examples of antenatal therapies that potentially avoid dangers to the fetus in the early stages of pregnancy. Phototherapy, exchange top-up transfusions, and intravenous immunoglobulin (IVIG) injections are examples of postnatal therapies (IVIG). IVIG therapy is highly recommended since it has a low risk of adverse medication responses and a wide range of survival rates. To avoid isoimmunization, anti-Rh D therapies are indicated. Noninvasive identification of the fetal human platelet antigen 1 genotype using cell-free fetal DNA obtained from maternal blood is one example of progress. This is still in the early stages of research as preventive medicine, the platelet equivalent of Rho (D) Immune Globulin Human (RhoGAM). The erythroblastosis fetalis is highly preventable when it is diagnosed at its early stages. Regular screening of all the patients with ABO incompatibility is necessary to prevent the risks of erythroblastosis fetalis.
01 2025 09 28 2022 121 124 1 10.1097/LWW.0000000000001000 lww.com ovid.com true 2022-04-21 2022-07-10 http://creativecommons.org/licenses/by-nc-sa/4.0 10.4103/ajts.ajts_50_22 https://journals.lww.com/10.4103/ajts.ajts_50_22 https://journals.lww.com/10.4103/ajts.ajts_50_22 Immunohematology Patale 37 64 2021 10.21307/immunohematology-2021-009 Statistical model for prediction of ABO hemolytic disease of the Fetus and Newborn in India Indian J Anaesth Mitra 58 524 2014 10.4103/0019-5049.144645 Blood groups systems Pediatric Health Med Ther Myle 12 491 2021 10.2147/PHMT.S327032 Hemolytic disease of the newborn: A review of current trends and prospects Blood Kline 4 1249 1949 10.1182/blood.V4.11.1249.1249 The pathogenesis of erythroblastosis fetalis World J Anemia Saxena 2 21 2018 10.5005/jp-journals-10065-0023 Immune hemolytic disease of the newborn J Pediatr Surg Derderian 50 50 2015 10.1016/j.jpedsurg.2014.10.027 The many faces of hydrops J Perinatol Shapiro 25 54 2005 10.1038/sj.jp.7211157 Definition of the clinical spectrum of kernicterus and bilirubin-induced neurologic dysfunction (BIND) J Perinatol Johnson 29 Suppl 1 S25 2009 10.1038/jp.2008.211 Clinical report from the pilot USA Kernicterus Registry (1992 to 2004) Vox Sang de Haas 109 99 2015 10.1111/vox.12265 Haemolytic disease of the fetus and newborn Am J Obstet Gynecol Van Kamp 192 171 2005 10.1016/j.ajog.2004.06.063 Complications of intrauterine intravascular transfusion for fetal anemia due to maternal red-cell alloimmunization Obstet Gynecol Howe 110 880 2007 10.1097/01.AOG.0000284623.15170.0d Intraperitoneal transfusion in severe, early-onset Rh isoimmunization Am J Obstet Gynecol Grannum 158 914 1988 10.1016/0002-9378(88)90094-4 The reversal of hydrops fetalis by intravascular intrauterine transfusions in severe is immune fetal anemia Expert Rev Hematol Ree 10 607 2017 10.1080/17474086.2017.1331124 Neonatal management and outcome in alloimmune hemolytic disease Am J Obstet Gynecol De Boer 198 4.e1 2008 10.1016/j.ajog.2007.05.030 Pediatric outcome in Rhesus hemolytic disease treated with and without intrauterine transfusion Bull N Y Acad Med Wiener 23 207 1947 Therapy of erythroblastosis fetalis with exchange transfusion Indian J Child Health (Bhopal) Naranje 06 503 2019 10.32677/IJCH.2019.v06.i09.009 Exchange transfusion in neonates: An experience from a tertiary care center in north India Transfus Med Hemother Mayer 45 429 2018 10.1159/000490154 Efficacy of antenatal intravenous immunoglobulin treatment in pregnancies at high risk due to alloimmunization to red blood cells Arch Dis Child Fetal Neonatal Ed Gottstein 88 F6 2003 10.1136/fn.88.1.F6 Systematic review of intravenous immunoglobulin in hemolytic disease of the newborn Pediatrics 114 297 2004 10.1542/peds.114.1.297 Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation Obstet Gynecol 130 E57 2017 10.1097/AOG.0000000000002232 Practice bulletin no. 181: Prevention of Rh D alloimmunization Am J Obstet Gynecol Bussel 225 120 2021 10.1016/j.ajog.2021.04.211 New developments in fetal and neonatal alloimmune thrombocytopenia